ADDED
During the three months ended August 31, 2025, no director or officer of the Company adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.
is a biotechnology company dedicated to the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients ( APIs ) using our patented DehydraTECH TM drug delivery technology.
DehydraTECH can be used with a wide range of active molecules including glucagon-like peptide-1 drugs ( GLP-1 ) and glucose-dependent insulinotropic polypeptide drugs ( GIP ), vitamins, pain medications, hormones, antivirals, nicotine and its analogs, and cannabinoids.
DehydraTECH can be implemented in a multitude of ingestible product formats including oral suspensions, tablets, capsules, foods, beverages, and oral pouches.
While the Company s primary focus is on pharmaceutical drug products, this technology extends across many product categories including nutraceuticals, foods and beverages.
The Company has developed extensive experience from the formulation and production of its demonstration products, in various formats, that enables it to provide expert advice to our licensees on the integration of DehydraTECH in their products for the purpose of providing more palatable and efficient delivery of bioactive molecules.
The Company was also granted four new patents (2 US and 2 AU) in our Compositions and Methods for Treating Epilepsy family, our first patent in the US for our Compositions and Methods of Treating Diabetes family, a new Japanese patent in our Compositions and Methods for Sublingual Delivery of Nicotine family and a second European patent in our Food Beverage Compositions Infused with Lipophilic Active Agents and Methods of Use Thereof family, which serves to further protect our exclusivity in the use of DehydraTECH with the treatment of epilepsy, diabetes, nicotine and food products.
Research and Development Lexaria incurred $8.2 million in R D expense during fiscal 2025.
These include, but are not limited to, ongoing programs to explore different therapeutic indications which DehydraTECH-enhanced drug products can be utilized to treat.
The study demonstrated a statistically significant reduction in human blood pressure ( BP ) from DehydraTECH-CBD, versus no statistical reduction in human blood pressure from the positive control.
REMOVED
is a biotechnology company dedicated to the enhancement of the bioavailability of a broad range of active pharmaceutical ingredients ( APIs ) using our patented DehydraTECH TM drug delivery-enabling platform technology.
DehydraTECH can be used with a wide range of active molecules including glucagon-like peptide-1 drugs ( GLP-1 ) and glucose -dependent insulinotropic polypeptide drugs ( GIP ), vitamins, pain medications, hormones, phosphodiesterase type 5 ( PDE5 ) inhibitors, antivirals, nicotine and its analogs, and cannabinoids.
DehydraTECH can be implemented in a multitude of ingestible or topically administered product formats including oral suspensions, tablets, capsules, foods, beverages, creams, lotions, and skin patches.
While the Company s primary focus is on pharmaceutical drug products, this technology extends across many product categories including foods, beverages, cosmetics and nutraceuticals.
Our current patent portfolio includes patent family applications or grants pertaining to Lexaria s compositions, methods of use in improving API bioavailability and palatability and methods of treatment for a range of therapeutic indications, orally or topically, for a wide variety of APIs encompassing cannabinoids; fat soluble vitamins; NSAID pain medications; and nicotine and its analogs.
And further expanded our patent protection for our other patent families.
These patents are as follows: our first ever Canadian patent granted in our 3 rd patent family, to use DehydraTECH to more efficiently deliver lipophilic active agents via stable ready-to-drink beverage formats our first ever European patent granted in our 6 th patent family, to use DehydraTECH to more efficiently deliver lipophilic active agents via transdermal or dermal delivery.
our first ever Canadian patent granted in new patent family #14, to use DehydraTECH to more efficiently deliver lipophilic agents in infused tobacco leaves or tobacco materials our first ever Japanese and Canadian patents in our 18 th patent family, to use DehydraTECH to enhance antiviral agents our first ever Canadian patent granted in our 20 th patent family, to apply DehydraTECH enhancement technology to the sublingual delivery of nicotine.
a new US patent granted in our 21 st patent family which recognizes DehydraTECH s ability, when combined with CBD, to treat hypertension.
four US patents granted in new patent family #24 which recognizes DehydraTECH s ability, when combined with CBD, to treat epilepsy Research and Development Lexaria incurred $2,360,565 in R D expense during fiscal 2024.